المؤلفون: Lim, Joseph K, Liapakis, Ann Marie, Shiffman, Mitchell L, Lok, Anna S, Zeuzem, Stefan, Terrault, Norah A, Park, James S, Landis, Charles S, Hassan, Mohamed, Gallant, Joel, Kuo, Alexander, Pockros, Paul J, Vainorius, Monika, Akushevich, Lucy, Michael, Larry, Fried, Michael W, Nelson, David R, Ben-Ari, Ziv, Group, HCV-TARGET Study

المصدر: Clinical Gastroenterology and Hepatology. 16(11)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Chronic Liver Disease and Cirrhosis, Hepatitis, Emerging Infectious Diseases, Hepatitis - C, Digestive Diseases, Clinical Research, Infectious Diseases, Liver Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents, Benzimidazoles, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Europe, Female, Fluorenes, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Liver Cirrhosis, Longitudinal Studies, Male, Middle Aged, North America, Prospective Studies, Ribavirin, Sofosbuvir, Sustained Virologic Response, Treatment Outcome, Young Adult, Real World, Viral Hepatitis, Therapy, HCV-TARGET, HCV-TARGET Study Group, Gastroenterology & Hepatology, Clinical sciences

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/0sg8z5mvTest

المؤلفون: Sulkowski, Mark S., Moon, Juhi S., Sherman, Kenneth E., Morelli, Giuseppe, Darling, Jama M., Muir, Andrew J., Khalili, Mandana, Fishbein, Dawn A., Hinestrosa, Federico, Shiffman, Mitchell L., Di Bisceglie, Adrian, Rajender Reddy, K., Pearlman, Brian, Lok, Anna S., Fried, Michael W., Stewart, Paul W., Peter, Joy, Wadsworth, Summer, Kixmiller, Scott, Sloan, Anquenette, Vainorius, Monika, Horne, Patrick M., Michael, Larry, Dong, Meichen, Evon, Donna M., Segal, Jodi B., Nelson, David R.

المصدر: Hepatology ; volume 74, issue 6, page 2952-2964 ; ISSN 0270-9139 1527-3350

الإتاحة: https://doi.org/10.1002/hep.32053Test

المؤلفون: Wang, Gary P., Schnell, Gretja L., Kort, Jens J., Sidhu, Gurjit S., Schuster, Layla, Tripathi, Rakesh L., Larsen, Lois, Michael, Larry C., Bergquist, Ken, Magee, Ashley, Patel, Chandni B., Whitlock, Joan A., Tamashiro, Ryan, Peter, Joy A., Fried, Michael W., Nelson, David R.

المساهمون: University of Florida, AbbVie Inc

المصدر: Journal of Hepatology ; volume 75, issue 4, page 820-828 ; ISSN 0168-8278

مصطلحات موضوعية: Hepatology

الإتاحة: https://doi.org/10.1016/j.jhep.2021.04.057Test
https://api.elsevier.com/content/article/PII:S0168827821003391?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0168827821003391?httpAccept=text/plainTest

المؤلفون: Lok, Anna S., Moon, Juhi, Sherman, Kenneth E., Khalili, Mandana, Fishbein, Dawn, Reddy, K. Rajender, Morelli, Giuseppe, Peter, Joy, Nelson, David R., Pearlman, Brian, Michael, Larry, Fried, Michael W., Segal, Jodi B., Sulkowski, Mark S.

المصدر: Clinical Gastroenterology and Hepatology ; volume 21, issue 2, page 546-548.e4 ; ISSN 1542-3565

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1016/j.cgh.2022.01.059Test
https://api.elsevier.com/content/article/PII:S1542356522001793?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1542356522001793?httpAccept=text/plainTest

المؤلفون: Fishbein, Diana H., Michael, Larry, Guthrie, Charles, Carr, Christine, Raymer, James

المساهمون: National Institute of Environmental Health Sciences

المصدر: Frontiers in Psychology ; volume 10 ; ISSN 1664-1078

الإتاحة: https://doi.org/10.3389/fpsyg.2019.01263Test

المؤلفون: Lok, Anna S., Sulkowski, Mark S., Kort, Jens J., Willner, Ira, Reddy, K. Rajender, Shiffman, Mitchell L., Hassan, Mohamed A., Pearlman, Brian L., Hinestrosa, Federico, Jacobson, Ira M., Morelli, Giuseppe, Peter, Joy A., Vainorius, Monika, Michael, Larry C., Fried, Michael W., Wang, Gary P., Lu, Wenjing, Larsen, Lois, Nelson, David R.

المساهمون: AbbVie

المصدر: Gastroenterology ; volume 157, issue 6, page 1506-1517.e1 ; ISSN 0016-5085

مصطلحات موضوعية: Gastroenterology, Hepatology

الإتاحة: https://doi.org/10.1053/j.gastro.2019.08.008Test
https://api.elsevier.com/content/article/PII:S0016508519411992?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0016508519411992?httpAccept=text/plainTest

المؤلفون: Evon, Donna M., Dong, Meichen, Reeve, Bryce B., Peter, Joy, Michael, Larry, Lok, Anna S., Nelson, David R., Stewart, Paul W.

مصطلحات موضوعية: sustained virological response, comparative effectiveness, direct acting antiviral, instrument, patient‐reported outcomes, survey, Oncology and Hematology, Health Sciences

وصف الملف: application/pdf

العلاقة: Evon, Donna M.; Dong, Meichen; Reeve, Bryce B.; Peter, Joy; Michael, Larry; Lok, Anna S.; Nelson, David R.; Stewart, Paul W. (2022). "Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial." Journal of Viral Hepatitis (9): 795-806.; https://hdl.handle.net/2027.42/174829Test; Journal of Viral Hepatitis; Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat Med. 2009; 28: 2509 ‐ 2530.; Gordon SC, Muir AJ, Lim JK, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV‐TARGET. J Hepatol. 2015; 62: 286 ‐ 293.; Kixmiller S, Sloan AP, Wadsworth S, et al. Experiences of an HCV Patient engagement group: a seven‐year journey. Res Involv Engagem. 2021; 7: 7.; Cella D, Riley W, Stone A, et al. The Patient‐Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self‐reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010; 63: 1179 ‐ 1194.; Reeve BB, Hays RD, Bjorner JB, et al. Psychometric evaluation and calibration of health‐related quality of life item banks: plans for the Patient‐Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; 45: S22 ‐ S31.; NIH PROMIS® Reference Populations. [Internet]. https://www.healthmeasures.net/scoreTest‐and‐interpret/interpret‐scores/promis/reference‐populations. Accessed September 17, 2021.; Evon DM, Amador J, Stewart P, et al. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018; 47: 1001 ‐ 1011.; Lee AC, Driban JB, Price LL, Harvey WF, Rodday AM, Wang C. Responsiveness and minimally important differences for 4 patient‐reported outcomes measurement information system short forms: Physical function, pain interference, depression, and anxiety in knee osteoarthritis. J Pain. 2017; 18: 1096 ‐ 1110.; Khanna D, Hays RD, Shreiner AB, et al. Responsiveness to change and minimally important differences of the patient‐reported outcomes measurement information system gastrointestinal symptoms scales. Dig Dis Sci. 2017; 62: 1186 ‐ 1192.; Amtmann D, Kim J, Chung H, Askew RL, Park R, Cook KF. Minimally important differences for patient reported outcomes measurement information system pain interference for individuals with back pain. J Pain Res. 2016; 9: 251 ‐ 255.; Kroenke K, Yu Z, Wu J, Kean J, Monahan PO. Operating characteristics of PROMIS four‐item depression and anxiety scales in primary care patients with chronic pain. Pain Med. 2014; 15: 1892 ‐ 1901.; Anderson RT, Baran RW, Dietz B, Kallwitz E, Erickson P, Revicki DA. Development and initial psychometric evaluation of the hepatitis C virus‐patient‐reported outcomes (HCV‐PRO) instrument. Qual Life Res. 2014; 23: 561 ‐ 570.; Anderson RT, Baran RW, Erickson P, Revicki DA, Dietz B, Gooch K. Psychometric evaluation of the hepatitis C virus patient‐reported outcomes (HCV‐PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Qual Life Res. 2014; 23: 877 ‐ 886.; Lu K. On efficiency of constrained longitudinal data analysis versus longitudinal analysis of covariance. Biometrics. 2010; 66: 891 ‐ 896.; Liang K, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre–post designs. Sankhyā Ind J Stat (Series B). 2000; 62: 134 ‐ 148.; Marcellin F, Roux P, Protopopescu C, Duracinsky M, Spire B, Carrieri MP. Patient‐reported outcomes with direct‐acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol. 2017; 11: 259 ‐ 268.; Evon DM, Kim HP, Edwards A, et al. "If I get cured, my whole quality of life will change": patients’ anticipated and actualized benefits following cure from chronic hepatitis C. Dig Dis Sci. 2021; 67: 100 ‐ 120.; Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health‐related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015; 63: 337 ‐ 345.; Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, Bourliere M. The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int. 2016; 36: 42 ‐ 48.; Serper M, Evon DM, Amador J, et al. Patient‐reported outcomes 12 months after hepatitis C treatment with direct‐acting antivirals: results from the PROP UP study. Liver Int. 2021; 41: 692 ‐ 704.; Schulte B, Schmidt CS, Manthey J, et al. Clinical and patient‐reported outcomes of direct‐acting antivirals for the treatment of chronic hepatitis C among patients on opioid agonist treatment: a real‐world prospective cohort study. Open Forum Infect Dis. 2020; 7: ofaa317.; Fagundes RN, Ferreira L, Pace FHL. Health‐related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct‐acting antivirals agents interferon‐free. PLoS One. 2020; 15: e0237005.; Karimi‐Sari H, Hosseini MA, Nikjoo N, Bagheri Baghdasht MS, Alavian SM. Patient‐reported outcomes of sleep, mood and quality of life after treatment of chronic hepatitis C infection using direct‐acting antiviral agents. Clin Microbiol Infect 2020; 26: 1093.e5‐.e8.; Ichikawa T, Miyaaki H, Miuma S, et al. Direct‐acting antivirals improved the quality of life, ameliorated disease‐related symptoms, and augmented muscle volume three years later in patients with hepatitis C virus. Intern Med. 2020; 59: 2653 ‐ 2660.; Goutzamanis S, Horyniak D, Doyle JS, Hellard M, Higgs P. Perceived physical health outcomes of direct‐acting antiviral treatment for hepatitis C: a qualitative study. Harm Reduct J. 2021; 18: 73.; O’Sullivan M, Jones AM, Gage H, et al. ITTREAT (Integrated Community Test ‐ Stage ‐ TREAT) Hepatitis C service for people who use drugs: Real‐world outcomes. Liver Int. 2020; 40: 1021 ‐ 1031.; Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend. 2016; 169: 101 ‐ 109.; Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open‐label, single‐arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018; 3: 153 ‐ 161.; Recommendations for testing, managing, and treating hepatitis C. January 2022. Accessed January 17, 2022. http://www.hcvguidelines.orgTest; Lang CA, Conrad S, Garrett L, et al. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage. 2006; 31: 335 ‐ 344.; Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010; 8: 1017 ‐ 1029.; Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta‐analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016; 150: 1599 ‐ 1608.; Kleefeld F, Heller S, Ingiliz P, et al. Interferon‐free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients: effect on cognitive function, fatigue, and mental health. J Neurovirol. 2018; 24: 557 ‐ 569.; McCarthy M, Ortega MR. Neurological complications of hepatitis C infection. Curr Neurol Neurosci Rep. 2012; 12: 642 ‐ 654.; Grover VP, Pavese N, Koh SB, et al. Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepat. 2012; 19: e89 ‐ e96.; Burgel B, Friesland M, Koch A, et al. Hepatitis C virus enters human peripheral neuroblastoma cells – evidence for extra‐hepatic cells sustaining hepatitis C virus penetration. J Viral Hepat. 2011; 18: 562 ‐ 570.; Tassi A, Gitto S, Piras C, et al. Cognitive, neurological and psychiatric disorders occurring in hepatitis C virus infection. Minerva Med. 2021; 112: 238 ‐ 245.; Monaco S, Mariotto S, Ferrari S, et al. Hepatitis C virus‐associated neurocognitive and neuropsychiatric disorders: advances in 2015. World J Gastroenterol. 2015; 21: 11974 ‐ 11983.; Tagliapietra M, Monaco S. Neuroimaging findings in chronic hepatitis C virus infection: Correlation with neurocognitive and neuropsychiatric manifestations. Int J Mol Sci. 2020; 21: 2478.; Ghany MG, Morgan TR. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases‐Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020; 71: 686 ‐ 721.; Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 1594 ‐ 1603.; Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir‐Elbasvir combination therapy for treatment‐naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163: 1 ‐ 13.; Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir‐based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014; 12: 1349 ‐ 1359.e13.; Evon DM, Sarkar S, Amador J, et al. Patient‐reported symptoms during and after direct‐acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019; 71: 486 ‐ 497.; Sung JC, Bosh C, Wyatt B, et al. Hepatitis C cure improved patient‐reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center. J Viral Hepat. 2020; 27: 350 ‐ 359.; Sulkowski MS, Moon J, Sherman K, et al. A pragmatic, randomized controlled trial of oral antivirals for the treatment of chronic hepatitis C: the prioritize study. Hepatology. 2021; 74: 2952 ‐ 2964.; Evon DM, Golin CE, Stoica T, et al. What’s important to the patient? Informational needs of patients making decisions about hepatitis C treatment. Patient. 2017; 10: 335 ‐ 344.

الإتاحة: https://doi.org/10.1111/jvh.13716Test
https://hdl.handle.net/2027.42/174829Test

المؤلفون: Michael, Larry L.

مصطلحات موضوعية: Higher Education, Motor ability, Testing

الإتاحة: http://rave.ohiolink.edu/etdc/view?acc_num=bgsu1670600632990338Test

المؤلفون: Arcuri, Pedro Braga, Thonney, Michael Larry, Schofield, Peter, Pell, Alice Nelson

المصدر: Pesquisa Agropecuária Brasileira. September 2003 38(9)

مصطلحات موضوعية: Ruminococcus albus, microbial ecology, animal nutrition

وصف الملف: text/html

الوصول الحر: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-204X2003000900008Test

المؤلفون: Pedro Braga Arcuri, Michael Larry Thonney, Peter Schofield, Alice Nelson Pell

المصدر: Pesquisa Agropecuária Brasileira, Vol 38, Iss 9, Pp 1073-1081 (2003)

مصطلحات موضوعية: Ruminococcus albus, ecologia microbiana, nutrição animal, microbial ecology, animal nutrition, Agriculture (General), S1-972

وصف الملف: electronic resource

العلاقة: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-204X2003000900008Test; https://doaj.org/toc/0100-204XTest; https://doaj.org/toc/1678-3921Test

الوصول الحر: https://doaj.org/article/2e31c3c45467444da7c8e6f741a21a90Test